PR 401
Alternative Names: Claudin 18.2 CAR-T - Shandong Boan Biotechnology; PR-401Latest Information Update: 27 Oct 2021
At a glance
- Originator Shandong Boan Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gastric cancer; Pancreatic cancer
Most Recent Events
- 16 Oct 2021 PR 401 is available for licensing as of 16 Oct 2021. https://www.boan-bio.com/en/contact.php?
- 16 Oct 2021 Preclinical trials in Gastric cancer in China (Parenteral) before October 2021 (Shandong Boan Biotechnology pipeline, October 2021)
- 16 Oct 2021 Preclinical trials in Pancreatic cancer in China (Parenteral) before October 2021 (Shandong Boan Biotechnology pipeline, October 2021)